在血液肿瘤患者中，COVID-19 可能表现为持续感染，并在很长一段时间内持续出现症状和病毒复制。关于这些患者首选治疗方案的数据很少。我们描述了我们对持续性 COVID-19 的血液肿瘤免疫功能低下患者进行为期五天的瑞德西韦和尼马瑞韦/利托那韦双重抗病毒治疗的经验。包括 15 名有淋巴瘤、CLL 和 MM 病史的患者。 8 名患者为男性，中位年龄为 74 岁。所有患者均立即出现临床和病毒学反应。 73% 的患者在治疗结束时 SARS-CoV-2 PCR 转为阴性，其余患者的 PCR 周期阈值 (CT) 有所增加，中位增加 6 个周期。经过三个月的随访后，60% 的患者保持完全的临床和病毒学缓解。没有人需要有创机械通气或死亡。我们观察到的副作用，如中性粒细胞减少症、乳酸血症和转氨酶升高，都是轻微的，而且几乎都是短暂的。我们的结论是，双重抗病毒治疗似乎是持续性 COVID-19 的有效治疗选择。版权所有 © 2023 日本化疗学会、日本传染病协会和日本感染预防与控制学会。由爱思唯尔有限公司出版。保留所有权利。

In hemato-oncological patients, COVID-19 can present as a persistent infection with ongoing symptoms and viral replication over a prolonged period of time. Data are scarce on the preferred treatment options for these patients. We describe our experience with a five-day course of dual anti-viral treatment with remdesivir and nirmatrelvir/ritonavir for hemato-oncological immunocompromised patients with persistent COVID-19. Fifteen patients with a history of lymphoma, CLL, and MM were included. Eight were male, median age was 74. All patients had an immediate clinical and virological response. In 73 % of patients, PCR for SARS-CoV-2 became negative at the end of treatment and the rest had an increase in PCR cycle threshold (CT) values, with a median increase of 6 cycles. After a follow-up of three months, 60 % of patients remained in full clinical and virological remission. None required invasive mechanical ventilation or died. The side effects we observed, neutropenia, lactatemia and elevated transaminases, were mild and almost all transient in nature. We conclude that dual anti-viral treatment appears to be a valid treatment option for persistent COVID-19.Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.